Evidence map›Paper›PMID 42371322›Full record

ArticleAnnals of surgical oncology2026

Is R1 Extended Liver Resection for Locally Advanced Intrahepatic Cholangiocarcinoma Justified? Nodal Status Not Margin Drives Prognosis.

Edoardo Maria Muttillo, Daniel Cherqui, Marc-Anthony Chouillard, Nicolas Golse, Oriana Ciacio, Gabriella Pittau, Chady Salloum, Daniel Azoulay, Marc-Antoine Allard, Daniel Pietrasz and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Edoardo Maria Muttillo *Henri-Bismuth Hepatobiliary Center, Paul-Brousse Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Saclay University, Villejuif, France.
Daniel Cherqui *Henri-Bismuth Hepatobiliary Center, Paul-Brousse Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Saclay University, Villejuif, France. daniel.cherqui@aphp.fr.
Marc-Anthony ChouillardHenri-Bismuth Hepatobiliary Center, Paul-Brousse Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Saclay University, Villejuif, France.
Nicolas GolseHenri-Bismuth Hepatobiliary Center, Paul-Brousse Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Saclay University, Villejuif, France.
Oriana CiacioHenri-Bismuth Hepatobiliary Center, Paul-Brousse Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Saclay University, Villejuif, France.
Gabriella PittauHenri-Bismuth Hepatobiliary Center, Paul-Brousse Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Saclay University, Villejuif, France.
Chady SalloumHenri-Bismuth Hepatobiliary Center, Paul-Brousse Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Saclay University, Villejuif, France.
Daniel AzoulayHenri-Bismuth Hepatobiliary Center, Paul-Brousse Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Saclay University, Villejuif, France.
Marc-Antoine AllardHenri-Bismuth Hepatobiliary Center, Paul-Brousse Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Saclay University, Villejuif, France.
Daniel PietraszHenri-Bismuth Hepatobiliary Center, Paul-Brousse Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Saclay University, Villejuif, France.
René AdamHenri-Bismuth Hepatobiliary Center, Paul-Brousse Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Saclay University, Villejuif, France.
Eric VibertHenri-Bismuth Hepatobiliary Center, Paul-Brousse Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Saclay University, Villejuif, France.
Pascal HammelDepartment of Medical Oncology, Paul-Brousse Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Saclay University, Villejuif, France.
Maïté LewinDepartment of Radiology, Paul-Brousse Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Saclay University, Villejuif, France.
Alina PascaleHenri-Bismuth Hepatobiliary Center, Paul-Brousse Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Saclay University, Villejuif, France.
Olivier RosmorducHenri-Bismuth Hepatobiliary Center, Paul-Brousse Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Saclay University, Villejuif, France.
Antonio Sa CunhaHenri-Bismuth Hepatobiliary Center, Paul-Brousse Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Saclay University, Villejuif, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeSurgery for locally advanced intrahepatic cholangiocarcinoma (LAICC) requires extended liver resections, often associated with vascular and/or biliary reconstruction. The benefits of these high-risk operations are still debated. The objective of this study was to analyze short, long-term outcomes, and futility after surgery for LAICC.

methodsA retrospective single-center study on the 2013-2024 period was conducted. LAICC was defined as mass-forming intrahepatic tumors 5 cm or more in size with hepatic vein/IVC contact or hepatic hilum contact or both and requiring extended liver resection (five segments or more). Futility was defined as deaths within 90 days or recurrence within 6 months of surgery.

results39 consecutive patients were analyzed, including (29) 74% women with a median age of 66 years (38-83 years). In 34 (88%) patients, a trisectionectomy (H145678 or H123458) was performed. Major vascular or biliary recontruction was required in 43.5% and 67%, respectively. Overall morbidity was 56%, with severe morbidity occurring in 8 (20%). The 90-day mortality was 5%. Median overall survival and recurrence-free survival was estimated at 58 and 23 months, respectively. Overall rate of futility was 15.4%. N+ has been shown to be the main factor affecting survival (p = 0.03 for overall survival and p = 0.01 for recurrence-free survival). R1 resection had no impact of overall or recurrence-free survival.

conclusionsOur study supports an aggressive surgical approach for LAICC. Anticipated R1 resection by necessity should not be considered a contraindication to surgery.

Indexed as

Advanced liver surgeryExtended hepatectomyExtended liver resectionLocally advanced intrahepatic cholangiocarcinomaR1 resection

Identifiers

PMID42371322

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.